DUBLIN, Nov. 28, 2014 /PRNewswire/ -- Research and Marketshas announced the addition of the "Global miRNA Market 2015-2019"report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
One of the main trends in this market is increased mergers and acquisitions. Many big pharmaceutical and biotechnology companies have acquired small life science and pharmaceutical companies to strengthen their business and expand their global presence.
According to the report, one of the major drivers in this market is increased investment in miRNA-based research and drug development. The demand for advanced diagnostics tools is increasing rapidly. miRNAs have a great potential in diagnostics and treatment of several severe diseases, including cancer, and cardiovascular and neurological disorders.
Further, the report states that one of the major challenges in this market is the delivery of miRNA-based drugs. Delivery of miRNA drugs into the desired cell or tissue in a body is a difficult procedure as any mistake in drug administration can lead to severe health defects.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Application
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Key Vendor Analysis
18. Other Reports in this Series
Companies Mentioned:
- Affymetrix
- Agilent Technologies
- Alnylam Pharmaceuticals
- Aparna Biosciences
- Applied Biological Materials
- AstraZeneca Pharmaceuticals
- Bio-Rad Laboratories
- Biogen Idec
- EMD Millipore
- Exiqon
- F. Hoffmann-La Roche
- Firefly Bioworks
- Fluidigm
- Genecopoeia
- Genosensor
- Gensignia
- Glaxosmithkline
- Groove Biopharma
- HTG Molecular Diagnostics
- Idera Pharmaceuticals
- Illumina
- InteRNA Technologies
- Integrated DNA Technologies
- LC Sciences
- Miltenyi Biotec
- MirnaTherapeutics
- Nanostring Technologies
- Norgen Biotek
- Novartis
- Origene Technologies
- Pfizer
- Phalanx Biotech
- Prolias Technologies
- Qiagen
- Quark Pharmaceuticals
- RXi Pharmaceuticals
- Regulus Therapeutics
- Rosetta Genomics
- Sanofi
- Santaris Pharma (Acquired by Roche)
- Silence Therapeutics
- System Biosciences
- Takara Bio
- Tekmira Pharmaceuticals
- Theradiag
- Thermo Fisher Scientific
- WaferGen Biosystems
- Wako Pure Chemical Industries
- miRagen Therapeutics
For more information visit http://www.researchandmarkets.com/research/qbnbvf/global_mirna
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
